Study of Development and Quantification Process for Toxic Metal Impurity Assessment in Pharmaceuticals

Name - Suryawanshi Ganesh Dhanaji
Supervisor Name - Dr Pranjali Shinde
Department of Chemistry
Institution Name - Malwanchal University, Indore

Abstract

This study presents a crucial investigation into the development and quantification of processes aimed at assessing toxic metal impurities in pharmaceutical products. The presence of toxic metals in pharmaceuticals can pose severe health risks to patients, making their accurate detection and quantification of paramount importance.The research begins by addressing the development aspect, emphasizing the creation of robust methodologies and protocols for the identification and measurement of toxic metal impurities. This step is critical in ensuring the reliability and consistency of results, which is essential for pharmaceutical safety.the study delves into the quantification process, which involves determining the concentration levels of these impurities within pharmaceutical formulations. Quantification is a pivotal step in assessing the potential health risks associated with exposure to toxic metals through medication intake.the study's focus and significance, it would benefit from briefly mentioning the specific analytical techniques or methodologies employed in the research. This would provide readers with a clearer understanding of the scientific rigor applied in this investigation.this study holds substantial promise in enhancing pharmaceutical quality control and safety. The development and quantification processes outlined here are crucial steps in ensuring that pharmaceutical products are free from harmful toxic metal impurities, ultimately safeguarding the well-being of patients and strengthening the pharmaceutical industry's commitment to product safety and quality.

Introduction

The pharmaceutical industry plays a pivotal role in safeguarding public health by manufacturing drugs and medications that are intended to treat, alleviate, or prevent various medical conditions. Ensuring the safety and efficacy of pharmaceutical products is a paramount concern, with extensive regulatory frameworks in place to maintain rigorous quality standards. Central to this concern is the presence of impurities, which can have adverse effects on patients' health. Among

these impurities, toxic metals pose a particular threat due to their potential for severe and long-lasting health consequences. Therefore, the accurate assessment and quantification of toxic metal impurities in pharmaceuticals have become a subject of increasing importance.Toxic metals such as lead, cadmium, mercury, and arsenic can enter the pharmaceutical supply chain through various routes, including raw materials, manufacturing processes, and packaging materials. Even trace amounts of these metals in pharmaceutical products can be harmful when consumed over extended periods. Therefore, there is an urgent need for robust and sensitive methods to detect and quantify these toxic metal impurities.

This study embarks on the critical mission of addressing this need by focusing on the development and quantification processes for assessing toxic metal impurities in pharmaceuticals. The research is driven by the overarching goal of enhancing pharmaceutical safety, ensuring that medications not only provide therapeutic benefits but also adhere to stringent quality standards.The development phase of this research involves the creation of novel methodologies and protocols for the reliable detection and identification of toxic metal impurities. This phase seeks to establish a comprehensive and systematic approach to identifying potential sources of contamination within the pharmaceutical production process. By doing so, it aims to mitigate the risks associated with toxic metal impurities at an early stage, ensuring the integrity of the final pharmaceutical product.The quantification process, a pivotal component of this study, revolves around accurately measuring the concentration levels of toxic metals within pharmaceutical formulations. This step is crucial for assessing the potential health risks posed by the consumption of these medications. The research will explore cutting-edge analytical techniques and instrumentation to achieve precise quantification, providing pharmaceutical manufacturers with the tools necessary to maintain the highest standards of safety and quality.this study represents a significant step forward in pharmaceutical quality control and safety. By addressing the critical issues surrounding toxic metal impurities through the development and quantification processes, it contributes to the ongoing efforts to ensure that pharmaceutical products consistently meet the stringent criteria for patient well-being and public health protection.

Heavy metals toxicity

Heavy metals toxicity represents a critical and multifaceted issue at the intersection of environmental science, public health, and industrial practices. These heavy metals, which include lead, mercury, cadmium, arsenic, and various others, are naturally occurring elements that, when present in excessive quantities, can exert deleterious effects on living organisms and ecosystems. Their widespread presence in the modern world, stemming from industrial activities, pollution sources, and even everyday products, has raised serious concerns regarding their potential to cause harm.

Heavy metals are so named due to their high atomic weight and density, distinguishing them from other elements. They find their way into the environment through mining, smelting, fossil fuel combustion, and agricultural practices, contaminating air, water, soil, and food sources. As they persist in the environment, heavy metals can accumulate in organisms, a process known as bioaccumulation, which magnifies their impact up the food chain.

The consequences of heavy metals toxicity are far-reaching and multifaceted. When humans or wildlife are exposed to elevated levels of these metals, a spectrum of health issues can arise. These range from acute poisonings, marked by symptoms such as nausea, vomiting, and organ damage, to chronic and insidious conditions like neurological disorders, developmental problems in children, and an increased risk of cancer.

Regulatory measures have been established worldwide to limit the allowable levels of heavy metals in various contexts, such as industrial emissions, food production, and drinking water quality. Yet, monitoring and enforcing these regulations remain ongoing challenges, particularly in regions with lax oversight.

Understanding heavy metals toxicity is not only a matter of scientific interest but also a matter of urgent public and environmental concern. This understanding empowers us to develop and implement effective mitigation strategies, including remediation methods to clean up contaminated sites, improved industrial practices to reduce emissions, and public education initiatives to minimize exposure risks.

Need of the Study

The study of the development and quantification process for toxic metal impurity assessment in pharmaceuticals is of utmost importance due to its direct impact on patient safety and well-being.

Toxic metal impurities, even in minuscule amounts, can lead to severe health complications when present in pharmaceutical products. Regulatory compliance is another compelling factor, as regulatory authorities worldwide have established stringent guidelines and limits for toxic metal impurities in pharmaceuticals. Failing to adhere to these standards can result in serious consequences for drug manufacturers, including product recalls and legal repercussions. Maintaining consistent product quality is a priority in the pharmaceutical industry, and a well-developed assessment and quantification process ensures that toxic metal impurity levels remain within acceptable limits, preventing batch rejections and potential harm to patients. In a global supply chain, understanding and controlling the sources of toxic metal impurities are crucial to safeguarding product integrity. With advancements in analytical techniques and instrumentation, this study allows pharmaceutical companies to leverage the latest technology to detect and quantify impurities more precisely, thus enhancing the overall safety and effectiveness of pharmaceutical products.

Significance of the study

The significance of conducting research on the development and quantification process for toxic metal impurity assessment in pharmaceuticals cannot be overstated. This study holds paramount importance in the realm of pharmaceuticals as it directly affects patient safety and public health. By refining and advancing the methods for detecting and quantifying toxic metal impurities, this research serves as a critical safeguard against potential harm caused by these contaminants in pharmaceutical products. It also facilitates regulatory compliance, ensuring that pharmaceutical companies adhere to stringent guidelines and limits set by regulatory authorities, thus preventing costly penalties and product recalls. Moreover, the study bolsters the assurance of consistent product quality, providing manufacturers with the means to uphold their reputation for delivering safe and effective medications. Embracing cutting-edge technologies and practices, as advocated by this research, enhances efficiency and reduces production costs, benefiting both manufacturers and patients. Furthermore, it strengthens the global pharmaceutical supply chain by mitigating risks associated with impurity contamination. As it contributes to scientific knowledge, this study fosters ongoing advancements in pharmaceutical practices and inspires consumer and healthcare provider confidence in the industry's commitment to safety and quality, ultimately promoting better healthcare outcomes. In essence, the significance of this study

resonates across various dimensions, safeguarding public health, regulatory adherence, industry efficiency, and scientific progress.

Literature Review

Gupta, N et al (2008) This study conducted an assessment of heavy metal contamination in vegetables cultivated using wastewater irrigation. Wastewater is often used for agricultural purposes due to water scarcity, but it can contain elevated levels of heavy metals, posing health risks through food consumption. A variety of commonly consumed vegetables were sampled from wastewater-irrigated fields and analyzed for heavy metal concentrations, including lead, cadmium, and mercury. The results revealed that several vegetables showed elevated levels of heavy metal contamination, exceeding recommended safety limits set by regulatory authorities. This contamination poses significant health concerns, as the consumption of such vegetables can lead to heavy metal exposure in humans, with potential long-term health implications. Findings from this study underscore the importance of careful monitoring and treatment of wastewater used for irrigation to ensure the safety of agricultural produce and the health of consumers.

Balaram, V. (2016). Recent advances in the determination of elemental impurities in pharmaceuticals have significantly improved the quality control and safety assessment of medicinal products. With stringent regulatory guidelines in place, pharmaceutical manufacturers must accurately measure and control elemental impurities to ensure product safety and compliance. Advanced analytical techniques such as inductively coupled plasma mass spectrometry (ICP-MS) and inductively coupled plasma optical emission spectroscopy (ICP-OES) have gained prominence for their precision, sensitivity, and ability to detect trace levels of impurities. Moreover, the International Council for Harmonisation (ICH) Q3D guidelines have provided a harmonized framework for evaluating and controlling elemental impurities, streamlining the global pharmaceutical industry's approach.

Thomas, R. (2018). The measurement of elemental impurities in pharmaceuticals is a pivotal undertaking to guarantee the safety and quality of medicinal products. Elemental impurities, which can encompass a spectrum of metals and trace elements, have the potential to enter pharmaceutical formulations unintentionally, raising concerns about patient health. To address these concerns, a stringent process is employed, beginning with the collection of representative

samples of pharmaceutical products or raw materials. These samples undergo meticulous preparation to make the impurities accessible for analysis. State-of-the-art analytical techniques like ICP-MS, ICP-OES, and AAS are then deployed to precisely quantify elemental impurities, often at extremely low concentrations. Calibration standards, quality control measures, and adherence to regulatory guidelines are integral components of this process, ensuring the accuracy and reliability of the results. Ultimately, the measurement of elemental impurities is a vital component of pharmaceutical quality control, assuring that medicinal products conform to regulatory requirements and pose minimal risks to patient health.

Rahman, N et al (2006) The importance of impurity analysis in pharmaceutical products cannot be overstated, as it serves as a cornerstone for safeguarding public health and maintaining product quality. At the core of this significance lies patient safety, with meticulous analysis acting as a shield against potential harm from contaminants. By quantifying impurities, pharmaceutical manufacturers ensure the consistency and reliability of their products, assuring patients that each dose is of the highest quality. Regulatory compliance is another critical factor, as health agencies worldwide demand rigorous impurity analysis to approve and monitor pharmaceuticals. Furthermore, impurity analysis extends its impact to the long-term health implications of trace contaminants, addressing potential risks that may not be immediately apparent. This scrutiny enhances the stability of pharmaceutical formulations, prevents batch rejections, maintains supply chain integrity, and fosters public confidence. Ultimately, the comprehensive analysis of impurities is a linchpin in the pharmaceutical industry, reassuring patients, healthcare providers, and regulatory bodies that pharmaceutical products are both safe and effective.

Holm, R., & Elder, D. P. (2016). Analytical advances in pharmaceutical impurity profiling represent a significant stride towards ensuring the safety, efficacy, and quality of pharmaceutical products. With the pharmaceutical industry under rigorous scrutiny by regulatory bodies worldwide, the ability to identify, characterize, and quantify impurities in drugs is critical. High-resolution mass spectrometry, coupled techniques, and comprehensive two-dimensional chromatography have revolutionized impurity profiling by enhancing resolution and precision, allowing the identification of even trace impurities. Additionally, NMR spectroscopy and chiral separation techniques provide invaluable insights into impurity structures, especially in complex

drug formulations. Automation and advanced software tools streamline data analysis, facilitating faster decision-making. Furthermore, the adoption of Quality by Design (QbD) principles ensures proactive management of impurities from drug development stages. With the advent of miniaturized and portable instruments, impurity analysis is no longer confined to the laboratory, enabling real-time monitoring in pharmaceutical manufacturing. Overall, these analytical advancements bolster pharmaceutical companies' ability to meet regulatory standards, mitigate risks, and, most importantly, safeguard patient health by delivering safer and higher-quality medications.

Shah, S. R et al (2012) Recent advances in impurity profiling in pharmaceutical analysis have brought about a transformation in the way pharmaceutical products are scrutinized for contaminants. These innovations encompass a range of sophisticated analytical techniques, such as high-resolution mass spectrometry, comprehensive two-dimensional chromatography, and nuclear magnetic resonance spectroscopy. These methods provide unprecedented sensitivity and precision in identifying and quantifying impurities, even at trace levels. Furthermore, chiral separation techniques have evolved to meet the specific requirements for enantiomeric impurity analysis, ensuring compliance with regulatory standards. Automation, advanced data processing tools, and the incorporation of Quality by Design (QbD) principles streamline the analytical process, making it more efficient and accurate.

Chahrour, O et al (2017) The development and validation of an ICP-MS method for the determination of elemental impurities in the TP-6076 Active Pharmaceutical Ingredient (API) according to USP<232>/<233> is a meticulous and essential process in the pharmaceutical industry. This analytical method's development involves fine-tuning the parameters to ensure it can detect impurities at or below the stringent regulatory limits specified by USP<232>/<233>. Once developed, the method undergoes rigorous validation to establish its accuracy, precision, and robustness. This validation process assesses various aspects of the method's performance, ensuring it meets the specific requirements for impurity determination.Sample preparation is a critical aspect, as it involves extracting and digesting the API, making impurities available for analysis. Calibration standards, with known impurity concentrations, are crucial for quantifying

these impurities accurately. Quality control measures and the analysis of control samples further verify the method's reliability and consistency.

Research Methodology

Heavy Metal Analysis in Cholic Acid by Q-ICP-MS

CholicacidofsynthesisgradeusedinthestudyisprocuredfromSuvidhinath laboratories. Nitric acid (65%), ethylene diamine tetraaceticacidsodiumsaltARgrade,andcertifiedreferencemetalstockstandardsolutions(1000mg/L)ofV,Co,Ni,Cd,Hg,Pb,andAs prepared in 2–3% HNO_3 of analytical grade were purchased fromMerck(Darmstadt,Germany).DeionizedwaterwaspreparedusingaMilli-QpluswaterpurificationsystemfromMillipore(Bedford,MA, USA). Yttrium standard for ICP TraceCERT® (1000 mg/L Y innitricacid),bismuthstandardforICPTraceCERT®(1000mg/LBiin nitric acid), nitric acid ≥69.0%, TraceSELECT™ for trace analysisfrom Honeywell were used for the study. All the autosampler vials,centrifugetubes,andplasticbottles,werecleanedbysoakingin20% v/v HNO_3 analytical grade reagent for 4 h, followed by rinsingwith deionized Milli-Q water thrice. Element impurities according toICHQ3D,Standard1(containing15ppmofArsenic(As),5ppmeachof Lead (Pb) and Cadmium (Cd), 30 ppm of Mercury (Hg), 50 ppm ofCobalt (Co), 100 ppm of Vanadium (V), 200 ppm of Nickel (Ni) andthree other elements i.e., 150 ppm each of Selenium (Se) and Silver(Ag) and 8 ppm of Thallium (Tl) multi-standard were procured fromSigma-Aldrich.

Samplepreparation

Weighed accurately about 100 mg of cholic acid commercial sampleinto a 15 mL calibrated plastic tube. Transferred 90 mL of (65%) HNO_3into 3000 mL volumetric flask containing 1000 mL of deionized watermixed well and diluted up to the mark with water, and shaken well.Added 3 mL of concentrated nitric acid to the sample in the sampletube and allowed the sample to digest with intermittent shaking. Aftersampledigestion,whenthesamplebecameclearandnomorefumesofnitric acid were evolved

from the sample tube, the content is made upto10 mLmarkwithwater.

Microwave Digestion

There are open and closed-vessel approaches to microwave-assisteddigestion.Aclosedvesselmethodisappropriateforamajorityofpharmaceuticalapplications. DigestionwasperformedusingMth2018–001,STD75manufacturedbyPerkinElmer16positionunitsizemicrowavedigestionsystem.Weighedaccurately0.2gsampleinto 10 mL volumetric flask and mixed it with 7.0 mL conc. HNO_3.Transferred into the digester vessel and selected the digestion methodasaboveanddigestedthesample.Cooledtotheroomtemperatureandtransferred into 10 mL volumetric flask and made up with purifiedwater.Pipettedout5.0mLinto10mLvolumetricflaskanddiluteuptothe mark with deionized water.

Standardstocksolutionsforcalibration

Standardstocksolutionsforcalibrationwerepreparedbytaking1.0mLofelementalimpuritiesaccordingtoICHQ3Dstandard,namely,1mLofastandardcontaining100ppmofVanadium(V),50ppmofCobalt(Co),200 ppm of Nickel (Ni), 5 ppm of Cadmium (Cd), 30 ppm of Mercury(Hg), 5 ppm of Lead (Pb) and 15 ppm of Arsenic (As) (Table S2). Thestandard stock solutions were then diluted to 20 mL with 2% nitricacid.Then,thesestocksolutionswerefurtherdilutedtomakedifferentlevelsofstandards forcalibration.

Spikedsamplesolution

Weighed accurately about 100 mg of sample into 15 mL calibratedplastic tube. The amount of standard stock solution 2 to be added isspecified in Table 2. Added 3 mL of conc. HNO_3 and allowed the sampleto digest with intermittent shaking. After sample digestion, when thesample become clear and all the fumes of nitric acid ceased to evolvefrom the sample tube, the digestion was made up to the mark withdeionizedwater.

Criteriaforvalidatingtheanalyticalmethod

For method validation, several criteria such as linear dynamic range,methodlinearity,accuracy,precision,limitofdetection(LOD),limitofquantification(LOQ),and measurementofuncertaintywereinvestigated and evaluated. In compliance with ICH Q2 (R1), Q-ICP-MSwas used to validate the analytical method for the quantification of V,Co,Ni, Cd, Hg, Pd andAs.

Q-ICP-MSanalysis

Sixreplicatereadingsof30sweepsovertheanalytemassrangewitha dwell time of 40 □ s for each mass per sweep were used in a typicalmethodofanalysis.Sampleaspirationfollowedbyrinsingwith2% HNO_3 wasdonefor60s.ForrunningtheinstrumentinKEDmode, 4.34mLmin-1ofHegaswasused.

CharacterizationofCholicacid

Fourier transform infrared spectra of the samples were recorded atroomtemperatureonaPerkinElmer,U.S.A,spectrometer:(Model:SpectrumGX).Thebackgroundd uetoairwasmeasured,theadsorbentwasaddedtoKBr,andthesamplewasscanned32timesoverafreque ncyrangeof400–4000cm^{-1}.^{1}Hand^{13}CNMRspectrawereobtainedusinga Bruker, Model: 400 MHz FTNMR, Avance III Spectrophotometer, and[$CDCl_3$]acetonewasusedasasolvent.Thechemicalshiftsarereportedin ppm with respect to the TMS internal reference. SEM-EDAX analysisof the samples was carried out on Philips, Netherlands Model: ESEMEDAXXL-30afterdepositingagoldcoating.Thevoltagewas30keV,andthefieldelectron sourcewasscanned ataresolutionof2 nm.

Research Problem

The pharmaceutical industry faces a critical challenge in ensuring the accurate and precise detection and quantification of toxic metal impurities in pharmaceutical products. Despite the

potential health risks associated with even trace levels of these impurities, there is a need to develop and implement robust assessment processes that can reliably identify the presence of toxic metals, address potential sources of contamination, and meet stringent regulatory requirements. The research problem centers on the development of effective methodologies and quality control measures to enhance the safety and quality of pharmaceutical products by minimizing toxic metal impurities throughout the manufacturing process, from raw material sourcing to final product release

Conclusion

The research focused on the development and quantification processes for assessing toxic metal impurities in pharmaceuticals has significant implications for pharmaceutical safety, quality control, and, ultimately, public health. This study has demonstrated the critical importance of addressing toxic metal impurities in pharmaceutical products, given their potential to cause harm to patients.The development phase of this research has highlighted the necessity of robust methodologies and protocols for the early detection and identification of toxic metal impurities. By systematically addressing potential sources of contamination within the pharmaceutical production process, this phase contributes to the prevention of toxic metal impurity-related issues before they can compromise product integrity.The quantification process, a core component of this study, is equally essential in assessing the potential health risks associated with toxic metal exposure through medications. The research has explored advanced analytical techniques to achieve precise quantification, offering pharmaceutical manufacturers the means to uphold rigorous safety and quality standards.

References

[1] Gupta, N., D. K. Khan, and S. C. Santra. "An assessment of heavy metal contamination in vegetables grown in wastewater-irrigated areas of Titagarh, West Bengal, India." Bulletin of Environmental Contamination and Toxicology 80 (2008): 115-118.

[2]Balaram, V. (2016). Recent advances in the determination of elemental impurities in pharmaceuticals–Status, challenges and moving frontiers. Trac trends in Analytical chemistry, 80, 83-95.

[3] Thomas, R. (2018). Measuring Elemental Impurities in Pharmaceuticals: A Practical Guide. CRC Press.

[4] Hseu, Zeng-Yei, Shaw-Wei Su, Hung-Yu Lai, Horng-YuhGuo, Ting-Chien Chen, and Zueng-Sang Chen. "Remediation techniques and heavy metal uptake by different rice varieties in metal-contaminated soils of Taiwan: New aspects for food safety regulation and sustainable agriculture." Soil Science & Plant Nutrition 56, no. 1 (2010): 31-52.

[5] Wuana, Raymond A., and Felix E. Okieimen. "Heavy metals in contaminated soils: a review of sources, chemistry, risks and best available strategies for remediation." International Scholarly Research Notices 2011 (2011).

[6] Alloway, Brian J., ed. Heavy metals in soils: trace metals and metalloids in soils and their bioavailability. Vol. 22. Springer Science & Business Media, 2012.

[7] Nriagu, Jerome O. "A history of global metal pollution." Science 272, no. 5259 (1996): 223-223.

[8] Abernethy, D. R., DeStefano, A. J., Cecil, T. L., Zaidi, K., Williams, R. L., & USP Metal Impurities Advisory Panel. (2010). Metal impurities in food and drugs. *Pharmaceutical research*, *27*, 750-755.

[9] Støving, C., Jensen, H., Gammelgaard, B., &Stürup, S. (2013). Development and validation of an ICP-OES method for quantitation of elemental impurities in tablets according to coming US pharmacopeia chapters. *Journal of pharmaceutical and biomedical analysis*, *84*, 209-214.

[10] Rahman, N., Azmi, S. N. H., & Wu, H. F. (2006). The importance of impurity analysis in pharmaceutical products: an integrated approach. *Accreditation and Quality Assurance*, *11*, 69-74.

[11] Holm, R., & Elder, D. P. (2016). Analytical advances in pharmaceutical impurity profiling. European Journal of Pharmaceutical Sciences, 87, 118-135.

[12] Crini, Grégorio. "Recent developments in polysaccharide-based materials used as adsorbents in wastewater treatment." Progress in polymer science 30, no. 1 (2005): 38-70.

[13] Shah, S. R., Patel, M. A., Naik, M. V., Pradhan, P. K., &Upadhyay, U. M. (2012). RECENT APPROCHES OF" IMPURITY PROFILING" IN PHARMACEUTICAL ANALYSIS: A REVIEW. *International Journal of pharmaceutical sciences and research*, *3*(10), 3603.

[14] Chahrour, O., Malone, J., Collins, M., Salmon, V., Greenan, C., Bombardier, A., ...& Dunwoody, N. (2017). Development and validation of an ICP-MS method for the determination

of elemental impurities in TP-6076 active pharmaceutical ingredient (API) according to USP< 232>/< 233. Journal of pharmaceutical and biomedical analysis, 145, 84-90.